NPS Pharmaceuticals Inc (NPSP)

45.97
0.01 0.02
Prev Close 45.96
Open 45.96
Day Low/High 45.95 / 45.99
52 Wk Low/High 22.11 / 46.01
Volume 9.49M
Avg Volume 4.75M
Exchange
Shares Outstanding 108.58M
Market Cap 4.99B
EPS -0.08
Div & Yield N.A. (N.A)
First Week Of September 21st Options Trading For NPS Pharmaceuticals (NPSP)

First Week Of September 21st Options Trading For NPS Pharmaceuticals (NPSP)

Investors in NPS Pharmaceuticals Inc. saw new options begin trading this week, for the September 21st expiration.

Stocks Under $10 Weekly Summary

Amid this week's slew of earnings reports, stocks pushed to new highs and we closed out one model portfolio position.

NPS Stock Hits New 52-Week High (NPSP)

NPS Stock Hits New 52-Week High (NPSP)

NPS Pharmaceuticals (Nasdaq:NPSP) hit a new 52-week high Monday as it is currently trading at $17.68, above its previous 52-week high of $17.66 with 478,548 shares traded as of 12:44 p.m. ET. Average volume has been 1.8 million shares over the past 30 days.

Stocks Under $10 Weekly Summary

As stocks continued their winning streak this week, and we added shares to two of our model portfolio positions.

NPS Reaches New 52-Week High (NPSP)

NPS Reaches New 52-Week High (NPSP)

NPS Pharmaceuticals (Nasdaq:NPSP) hit a new 52-week high Monday as it is currently trading at $16.50, above its previous 52-week high of $16.47 with 389,952 shares traded as of 11:40 a.m. ET. Average volume has been 1.9 million shares over the past 30 days.

Stocks Under $10 Weekly Summary

We remain confident with the composition of the model portfolio ahead of the second-quarter earnings.

Stocks Under $10 Weekly Summary

Amid the week's volatility, a new name joined the model portfolio and we also added shares to an existing position.

Short Interest Jumps 13% For NPSP

Short Interest Jumps 13% For NPSP

The most recent short interest data has been released by the NASDAQ for the 06/14/2013 settlement date, which shows a 1,271,400 share increase in total short interest for NPS Pharmaceuticals Inc. , to 10,956,939, an increase of 13.13% since 05/31/2013.

Stocks Under $10 Weekly Summary

We used the volatility this week to make several changes to the model portfolio, which included adding a new position.

NPS Going Strong With Gattex

NPS Going Strong With Gattex

Sales of short bowel syndrome drug Gattex have been strong despite worries over price, says Francois Nader CEO of NPS Pharmaceuticals.

Findings Presented At ENDO 2013 Support Therapeutic Potential Of Natpara® As Parathyroid Hormone Replacement Therapy In Patients With Hypoparathyroidism

Findings Presented At ENDO 2013 Support Therapeutic Potential Of Natpara® As Parathyroid Hormone Replacement Therapy In Patients With Hypoparathyroidism

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, yesterday presented findings supporting the...

Initial Findings From PARADOX, Largest And Most Comprehensive Research Analyzing The Burden Of Hypoparathyroidism, Reveals Collection Of Nearly 40 Physical, Cognitive, Emotional Symptoms

Initial Findings From PARADOX, Largest And Most Comprehensive Research Analyzing The Burden Of Hypoparathyroidism, Reveals Collection Of Nearly 40 Physical, Cognitive, Emotional Symptoms

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, yesterday presented initial findings from ...

Stocks Under $10 Weekly Summary

During an up-and-down week for stocks, we used the volatility to build up one of our model portfolio positions.

NPS Pharmaceuticals’ President And CEO Dr. Francois Nader Receives Ernst & Young Entrepreneur Of The Year® 2013 Award In New Jersey

NPS Pharmaceuticals’ President And CEO Dr. Francois Nader Receives Ernst & Young Entrepreneur Of The Year® 2013 Award In New Jersey

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that president and chief ...

Stocks Under $10 Weekly Summary

We used this week's volatility to sell shares from one model portfolio name and some of the funds to add to another.

NPS Reaches New 52-Week High (NPSP)

NPS Reaches New 52-Week High (NPSP)

NPS Pharmaceuticals (Nasdaq:NPSP) hit a new 52-week high Tuesday as it is currently trading at $16.44, above its previous 52-week high of $16.37 with 278,157 shares traded as of 9:56 a.m. ET. Average volume has been 2.1 million shares over the past 30 days.

'Mad Money' Lightning Round: Don't Sell Weyerhaeuser

'Mad Money' Lightning Round: Don't Sell Weyerhaeuser

Cramer likes NPS Pharmaceuticals, prefers Honeywell over Xerox but is avoiding 3D Systems and Triquint Semiconductor.

Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer's 'Mad Money' Recap: Next Week's Game Plan

The markets will continue to live in a bizarre world where any good economic news will spook institutional traders and send the markets back into a tailspin, Cramer said.

Stocks Under $10 Weekly Summary

The week ended on a sour note, but we used its earlier strength to exit one model portfolio position and trim one other.

Stocks Under $10 Weekly Summary

As stocks ended their four-week winning streak this week, we used the volatility to trim one model portfolio position.

Trimming a Pharmaceutical Position

The stock has doubled over the past three months and we don't want to be greedy with our gains.

Stocks Under $10 Weekly Summary

We used the strength this week to take some profits in three model portfolio positions, and we added to two other holdings.

Ratings Changes Coming on 5/14/2013

Upgrades: AUDC, BLDR, CLCT, DMD, KBR, NPSP, OME, SIX Downgrades: PAR, RDNT, SATS, UCFC, UPG Initiations: None

NPS Pharmaceuticals Inc Stock Upgraded (NPSP)

NPS Pharmaceuticals Inc Stock Upgraded (NPSP)

NPS Pharmaceuticals (Nasdaq:NPSP) has been upgraded by TheStreet Ratings from a sell to hold.

Stocks Under $10 Weekly Summary

As earnings season wrapped up this week, we added shares to one model portfolio position and trimmed one other.

Earnings Produce Few Surprises

This pharmaceuticals name posted solid quarterly results today, we believe its new products can continue to drive growth.

Previewing a Pharmaceutical Company

We'll be listening for details on the latest prescription trends for its products when this name reports tomorrow.

Stocks Under $10 Weekly Summary

Amid a volatile week for stocks, we used a significant decline in one model portfolio name to build up our position.

Stocks Under $10 Weekly Summary

We used the market rally early this week to trim two model portfolio positions and we added shares to three other names.

Taking Profit in Pharma

We don't want to be greedy ahead of this company's next quarterly report.